What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34672
Abstract: represented in clinical trials, and to frame opportunities to improve patient outcomes. As a result, RWE is not a panacea to resolve all residual uncertainties from clinical trial results, and well ‐ adjusted multivariate analysis… read more here.
Keywords: health; clinical trials; cdk4 inhibitors; reality cdk4 ... See more keywords
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.
Sign Up to like & getrecommendations! Published in 2017 at "Interventional cardiology clinics"
DOI: 10.1016/j.iccl.2016.08.010
Abstract: There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently shown to reduce clopidogrel… read more here.
Keywords: genetic determinants; cardiology; clinical implications; inhibitors clinical ... See more keywords
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.10.003
Abstract: PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair pathway, namely BRCA1/2 mutations. Given the limited therapeutic options for… read more here.
Keywords: parp inhibitors; inhibitors clinical; parp; resistance ... See more keywords
Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle‐income Latin American country
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.13951
Abstract: Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%‐30%. Inhibitor prevalence differs among populations. Some studies report… read more here.
Keywords: prevalence inhibitors; patients haemophilia; characteristics patients; prevalence ... See more keywords
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27154964
Abstract: Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands… read more here.
Keywords: pde4 inhibitors; 2010 early; overview pde4; clinical trials ... See more keywords